Current Evidence on the Use of Antifilarial Agents in the Management of bancroftian Filariasis

• Published in: Journal of Tropical Medicine
• Main Authors: Sumadhya Deepika Fernando, Chaturaka Rodrigo, Senaka Rajapakse
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2011
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Arctic
• Online Access: https://doi.org/10.1155/2011/175941; https://doaj.org/article/ff0cf969ac304a49a8057d4400212dbe

Many trials have explored the efficacy of individual drugs and drug combinations to treat bancroftian filariasis. This narrative review summarizes the current evidence for drug management of bancroftian filariasis. Diethylcarbamazine (DEC) remains the prime antifilarial agent with a well-established microfilaricidal and some macrofilaricidal effects. Ivermectin (IVM) is highly microfilaricidal but minimally macrofilaricidal. The role of albendazole (ALB) in treatment regimens is not well established though the drug has a microfilaricidal effect. The combination of DEC+ALB has a better long-term impact than IVM+ALB. Recent trials have shown that doxycycline therapy against Wolbachia, an endosymbiotic bacterium of the parasite, is capable of reducing microfilaria rates and adult worm activity. Followup studies on mass drug administration (MDA) are yet to show a complete interruption of transmission, though the infection rates are reduced to a very low level.